Although this supports previous expert recommendations from the “CAPS Consortium” to consider pancreatic cancer screening of BRCA2 mutation carriers with family history of the disease [6], it questions the methods and efficacy for such screening. This evidence concerns the gene BRCA2 and pancreatic neoplasm.